The value of surgery in ovarian cancer

Share :
Published: 24 May 2019
Views: 3846
Rating:
Save
Prof Christina Fotopoulou - Queen Charlotte's and Chelsea Hospital, London, UK

Prof Christina Fotopoulou talks to ecancer at the Ovacome Member's Day 2019 about the value of surgery in ovarian cancer.

She outlines the importance of a need for extra expertise in specialised cancer centres due to the individual nature of the disease.

Prof Fotopoulou also discusses the situations where it could be advisable not to undergo surgery and also the complications of operations compared with other treatments.

Related Videos

ASCO GU 2026: Updates in metastatic prostate cancer

Dr María Natalia Gandur Quiroga - Instituto de Oncología 'Ángel H. Roffo', Universidad de Buenos Aires, Argentina
ASCO GU 2026: Updates in metastatic prostate cancer ( Dr María Natalia Gandur Quiroga - Instituto de Oncología 'Ángel H. Roffo', Universidad de Buenos Aires, Argentina )
17 Mar 2026

ASCO GU 2026: Updates in localised prostate cancer

Dr María Natalia Gandur Quiroga - Instituto de Oncología 'Ángel H. Roffo', Universidad de Buenos Aires, Argentina
ASCO GU 2026: Updates in localised prostate cancer ( Dr María Natalia Gandur Quiroga - Instituto de Oncología 'Ángel H. Roffo', Universidad de Buenos Aires, Argentina )
17 Mar 2026

ESMO 2024: Best practice in HRRm testing in patients with metastatic prostate cancer

Prof Karim Fizazi, Dr Anders Bjartell, Dr Niven Mehra and Prof Eleni Efstathiou
ESMO 2024: Best practice in HRRm testing in patients with metastatic prostate cancer ( Prof Karim Fizazi, Dr Anders Bjartell, Dr Niven Mehra and Prof Eleni Efstathiou )
19 Sep 2024

Tisotumab vedotin shows clinically meaningful OS improvement versus chemo for metastatic cervical cancer

Prof Ignace Vergote - UZ Leuven, Leuven, Belgium
Tisotumab vedotin shows clinically meaningful OS improvement versus chemo for metastatic cervical cancer ( Prof Ignace Vergote - UZ Leuven, Leuven, Belgium )
7 Nov 2023

2 year recurrence free survival benefit for resectable melanoma treated with neoadjuvant/adjuvant pembrolizumab

Dr Sapna Patel - MD Anderson Cancer Center, Houston, USA
2 year recurrence free survival benefit for resectable melanoma treated with neoadjuvant/adjuvant pembrolizumab ( Dr Sapna Patel -  MD Anderson Cancer Center, Houston, USA )
2 Nov 2023

Feasibility and safety of boost at 74 Gy based on interim FDG-PET during thoracic radio-chemotherapy for NSCLC patients

Prof Gerard Zalcman - Université de Paris, Paris, France
Feasibility and safety of boost at 74 Gy based on interim FDG-PET during thoracic radio-chemotherapy for NSCLC patients ( Prof Gerard Zalcman - Université de Paris, Paris, France )
27 Oct 2023

Adjuvant radiotherapy has no benefit following radical prostatectomy

Prof Noel Clarke - The Christie NHS Foundation Trust, Manchester, UK
Adjuvant radiotherapy has no benefit following radical prostatectomy ( Prof Noel Clarke - The Christie NHS Foundation Trust, Manchester, UK )
27 Oct 2023

Short-course radiation as effective as standard treatment for breast cancer patients choosing reconstruction after mastectomy

Dr Julia Wong - Dana-Farber Brigham Cancer Center, Boston, USA
Short-course radiation as effective as standard treatment for breast cancer patients choosing reconstruction after mastectomy ( Dr Julia Wong - Dana-Farber Brigham Cancer Center, Boston, USA )
6 Oct 2023

OncoAlert Round Up for September 15-21, 2023

Dr Gil Morgan - Executive Director, OncoAlert
OncoAlert Round Up for September 15-21, 2023 ( Dr Gil Morgan - Executive Director, OncoAlert )
25 Sep 2023